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Introduction: Multiple sclerosis (MS) is the most common inflammatory demyelinating disorder of the central
nervous system (CNS). Minocycline ameliorates the clinical severity of MS and exhibits antiinflammatory,
neuroprotective activities, and good tolerance for long-term use, whereas it is toxic to the CNS. Recently, the
immunomodulation and neuroprotection capabilities of human bone marrow mesenchymal stem cells (hBM-MSCs)
were shown in experimental autoimmune encephalomyelitis (EAE). In this study, we evaluated whether the
combination of hBM-MSCs and a low-dose minocycline could produce beneficial effects in EAE mice.
Methods: The sensitivity of hBM-MSCs to minocycline was determined by an established cell-viability assay.
Minocycline-treated hBM-MSCs were also characterized with flow cytometry by using MSC surface markers and
analyzed for their multiple differentiation capacities. EAE was induced in C57BL/6 mice by using immunization with
MOG35-55. Immunopathology assays were used to detect the inflammatory cells, demyelination, and
neuroprotection. Interferon gamma (IFN-γ)/tumor necrosis factor alpha (TNF-α) and interleukin-4 (IL-4)/interleukin-10
(IL-10), the hallmark cytokines that direct Th1 and Th2 development, were detected with enzyme-linked
immunosorbent assay (ELISA). terminal dUTP nick-end labeling (TUNEL) staining was performed to elucidate the cell
apoptosis in the spinal cords of EAE mice.
Results: Minocycline did not affect the viability, surface phenotypes, or differentiation capacity of hBM-MSCs, while
minocycline affected the viability of astrocytes at a high dose. In vivo efficacy experiments showed that combined
treatment, compared to the use of minocycline or hBM-MSCs alone, resulted in a significant reduction in clinical
scores, along with attenuation of inflammation, demyelination, and neurodegeneration. Moreover, the combined
treatment with hBM-MSCs and minocycline enhanced the immunomodulatory effects, which suppressed
proinflammatory cytokines (IFN-γ, TNF-α) and conversely increased anti-inflammatory cytokines (IL-4, IL-10). In
addition, TUNEL staining also demonstrated a significant decrease of the number of apoptotic cells in the
combined treatment compared with either treatment alone.
Conclusions: The combination of hBM-MSCs and minocycline provides a novel experimental protocol to enhance
the therapeutic effects in MS.
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Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disease of the central nervous system (CNS). The
characteristics of MS include multifocal perivascular
mononuclear cell infiltrates in the CNS, demyelination,
and neuronal loss. To date, several therapeutic strategies
have been studied in experimental autoimmune ence-
phalomyelitis (EAE) mice. However, further improvement
in MS therapeutics is necessary, with a focus on preven-
ting the infiltration of inflammatory cells into the CNS
and/or preventing demyelination and apoptotic cell death.
Minocycline is a semisynthetic tetracycline analogue
suitable for treatment of CNS disorders because it is
capable of penetrating the blood–brain barrier and has
antiinflammatory and antiapoptotic activities. It is effect-
ive in delaying progression in numerous neurodegenera-
tive diseases. The use of minocycline in EAE and MS
can attenuate disease activity [1,2] and reduce magnetic
resonance imaging (MRI)-detected gadolinium enhance-
ments within 2 months of treatment [3]. In addition,
minocycline exerts neuroprotective effects in EAE by
protecting axons from demyelination; attenuating neur-
onal death [4]; and modulating immune differentiation
from a Th1 toward a Th2 phenotype, thereby reducing
T-cell infiltration into the spinal cord [2,5]. The pa-
thogenic complexity and heterogeneity of MS makes
combination therapy an attractive treatment strategy.
Previous studies of suboptimal doses of minocycline
combined with interferon-beta (IFN-β), methylpredniso-
lone, or atorvastatin have demonstrated better outcomes
in EAE than any of these drugs used [6-8]. However,
minocycline can cause adverse effects, such as systemic
lupus erythematosus and serum sickness [9,10], and is
toxic to the CNS at high doses [11,12]. Therefore, it is
necessary to find a combined therapy that requires a low
dose of minocycline.
Human bone marrow mesenchymal stem cells (hBM-
MSCs) have been viewed as a potential treatment for
neurodegenerative diseases. They are easily obtained
from human bone marrow and escape immune system
surveillance because they possess cell-surface antigens
that are poorly recognized by T cells [13], and facili-
tate engraftment. hBM-MSCs are able to suppress
T-lymphocyte activation and proliferation, induce a Th2-
polarized immune response, and promote endogenous
repair, thus demonstrating immunomodulatory capa-
cities both in vitro and in vivo [14-17]. In addition,
previous studies have shown that on engraftment, hBM-
MSCs selectively migrate and target damaged tissue,
providing a feasible and practical way to combat inflam-
mation, reduce demyelination, and protect neurons and
axons in EAE [18-20].
In this study, we investigated whether the combi-
nation of hBM-MSCs and minocycline would producebeneficial effects in EAE mice. We demonstrate that the
combination treatment delayed clinical onset; attenuated
clinical severity, inflammation, and demyelination; and
enhanced neuroprotection when compared with either
treatment alone. Most important, this combination treat-
ment enhanced immunomodulatory functions, sugges-
ting that it has potential to improve the functional
recovery of patients with MS.Materials and methods
Cell culture and reagents
hBM-MSCs were purchased from (Lonza, Walkersville,
IN, USA). Cells were thawed, and initiation of the cul-
ture process was performed according to the manufac-
turer’s instructions. Cells were plated in a culture dish
and cultured with hBM-MSC basal medium supplemen-
ted with MSC growth supplement at 37°C in a humidi-
fied atmosphere containing 5% CO2. Astrocytes were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were grown in
Dulbecco modified Eagle medium (Invitrogen, Carlsbad,
CA, USA) containing 10% fetal bovine serum. Minocy-
cline was purchased from Sigma-Aldrich (St. Louis,
MO, USA), dissolved in distilled water at 1 mM and
filter-sterilized.Assessment of MSC viability and characterization to
minocycline
hBM-MSCs or astrocytes were seeded in 24-well plates
(8 × 103) or 96-well plates (5 × 103), respectively. Increa-
sing amounts of minocycline were added to confirm
minocycline hBM-MSC or astrocyte-specific cytotox-
icity. Twenty-four hours after treatment, cell viability
was analyzed with the (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) assay (Sigma-Aldrich). Fluo-
rescence-activated cell sorting (FACS) was performed
to evaluate cell-surface markers. hBM-MSCs treated
with or without minocycline were trypsinized, washed
with phosphate-buffered saline (PBS), and then incu-
bated with phycoerythrin-conjugated mouse anti-human
CD34, CD45, HLA-DR, CD73, CD90, and CD44 anti-
body (all from BD Bioscience, Franklin Lakes, NJ, USA).
The differentiation of hBM-MSCs to adipogenic or os-
teogenic lineages was induced, as described previously,
with or without minocycline [21]. After 3 to 4 weeks cul-
ture in induction medium with or without minocycline,
the differentiated cells were fixed with 10% formalde-
hyde. Adipocytes were detected by staining the lipid
droplets in the cell by using 0.3% Oil Red O staining for
10 minutes. Osteocytes were detected with calcium
phosphate deposits by using 0.2% Alizarin Red S staining
for 20 minutes.
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All animal protocols were approved by the Institutional
Animal Care and Use Committee of the Catholic Uni-
versity Medical College. EAE was induced in C57BL/
6 mice (female, 11 weeks old) by immunization with
MOG35-55 (Hooke Labs, Lawrence, MA, USA). The
mice were injected subcutaneously at two sites with a
total of 200 μg of MOG35-55 emulsified in complete
Freund adjuvant (CFA) containing 6 mg/ml of Myco-
bacterium tuberculosis. Two and 24 hours after the
MOG35-55 injection, the mice received 100 ng pertussis
toxin intraperitoneally. Paralysis as clinical evidence of
EAE was assessed daily starting on day 5 after im-
munization, when all the mice were still clinically nor-
mal. Clinically, animals were scored as follows: 0, no
clinical signs; 1, limp tail; 2, partial hind-leg paralysis; 3,
complete hind-leg paralysis; 4, complete hind-leg paraly-
sis and partial front-leg paralysis; and 5, moribund or
dead. Mice were randomly divided into four groups: PBS
(n = 10), hBM-MSCs (1.5 × 106 cells in 100 μl PBS for
each mouse, intravenous injection, n = 10), minocycline
(10 mg/kg, intraperitoneal injection, n = 10), and com-
bination of hBM-MSCs and minocycline (n = 10). All
treatments started on day 7 after immunization. Mino-
cycline was administered intraperitoneally for consecu-
tive days until death.
Immunohistopathology
Mice were killed on day 46 after immunization. Frozen
sections were obtained from lumbar spinal cords and
processed for hematoxylin and eosin (H&E) staining,
Luxol Fast Blue (LFB) staining, and immunofluorescence
staining to evaluate the presence of inflammatory cells,
demyelination, neuronal loss, and activated gliocytes,
according to standard protocols. For immunofluores-
cence, lumbar spinal cord sections were incubated at
4°C overnight with the following antibodies: mono-
clonal mouse anti-glial fibrillary acidic protein (GFAP;
Millipore, Temecula, CA, USA), polyclonal rabbit anti-
ionized calcium-binding adaptor molecule 1 (Iba1; Wako
Pure Chemical Industries, Osaka, Japan), monoclonal
mouse antineuronal nuclear antigen (NeuN; Chemicon
International, Temecula, CA, USA), monoclonal mouse
anti-CD4 (BD Biosciences Pharmingen, CA, USA), and
polyclonal rabbit anti-mouse myelin basic protein (MBP;
Millipore, Billerica, MA, USA). Antibody staining was
visualized with anti-rabbit and anti-mouse Cy3-conju-
gated secondary antibodies (Jackson ImmunoResearch,
West Grove, PA, USA). Specificity of immunoreactivity
was confirmed by the absence of an immunohisto-
chemical reaction in sections from which primary or
secondary antibodies were omitted. In all sections, coun-
terstaining of cell nuclei was carried out by incubating
the sections with 4-6-diamidino-2-phenyindole (DAPI;Roche, Penzberg, Germany) for 10 minutes. All images
were acquired by using an LSM 700 confocal micro-
scope (Carl Zeiss, Oberkochen, Germany).
Determination of serum cytokines with enzyme-linked
immunosorbent assay
Serum was obtained from all animals of each treatment
group on day 40 after immunization. ELISA was per-
formed by using Quantikine immunoassay from R&D
Systems (Madison, WI, USA). In brief, sera were incu-
bated in the precoated 96-well plates for 4 hours at
room temperature (RT). After three washes, conjugated
antibody was added for 2 hours at RT, incubated in the
substrate solution for 30 minutes, and the reaction was
stopped by the addition of stop solution. The optical
density of each well was determined by using a micro-
plate reader at 450 nm.
Determination of the apoptotic cell death with TUNEL
assay
Apoptotic cells were visualized by using a terminal
deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) assay kit (Roche, Basel, Switzerland) deve-
loped by using Cy3-conjugated streptavidin (Jackson
ImmunoResearch Laboratories). In brief, slides were
placed in the distilled water at 60°C for 2 hours, af-
ter washing with terminal deoxynucleotidyl transferase
(TdT) labeling buffer, TUNEL reaction mixture was
pipetted onto the sections, which were then incubated in
a humidified chamber at 37°C for 1 hour. The reaction
was stopped by adding terminating buffer. Counter-
staining of cell nuclei was carried out by incubating the
sections with DAPI for 10 minutes. In addition to
characterization of the apoptotic cell, the sections were
then double labeled with NeuN, GFAP, Ib-1, and CD4,
respectively.
Quantification and statistical analysis
Quantification was performed by an examiner blinded to
the treatment status of each animal. Six to eight sections
from each of three transverse lumbar spinal cords col-
lected from each group were qualitatively analyzed. H&E
and LFB stains were viewed with a Slide Scanner for
Digital Pathology (SCN400; Leica, Wetzlar, Germany)
under a × 200 objective lens, and immunofluores-
cence was viewed with a confocal microscope under
a × 200 objective lens. All images were measured with
MetaMorph software, version 7.5 (Molecular Devices,
Sunnyvale, CA, USA). The average number of infiltrated
cells, positive staining cell number, or fluorescence in-
tensity was presented as the cell number or fluorescence
intensity in the lesion sites under each photographed ob-
jective magnification. Lesion size was determined with
quantitative histologic analysis of the LFB-counterstained
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sion area under photographed objective magnification.
Data are presented as mean ± SEM. All statistical com-
parisons between the groups were examined by using
one-way analysis of variance (ANOVA) with post hoc
Bonferroni corrections. The P values <0.05 were consid-
ered statistically significant.
Results
Effects of minocycline on hBM-MSC viability, phenotype,
and differentiation
To examine whether minocycline could affect the via-
bility of hBM-MSCs and astrocytes, these cells were
grown in media containing various concentrations of
minocycline. The viability of hBM-MSCs was not af-
fected until 10 μM, and 8 to 10 μM decreased astrocyte
viability (Figure 1A). The evident toxicity to astrocytes,
which is a representative cell type of the CNS, prompted
the use of a lower dose of minocycline for the following
in vivo combination experiments. In addition, to investi-
gate the characteristic features of minocycline-treated
hBM-MSCs, we evaluated the surface phenotypes ofFigure 1 Effects of minocycline on hBM-MSC stability. (A) hBM-MSC an
minocycline (0 to 10 μM) treatment. Minocycline did not affect hBM-MSC v
decreased astrocyte viability. Points, mean; bars, SEM. (B) FACS analysis of t
lines) and minocycline-treated hBM-MSCs (red lines) were labeled with ant
change surface-marker expression; hBM-MSCs expressed CD90, CD44, and C
minocycline on the differentiation potential of hBM-MSCs. Minocycline did
osteogenic lineages, as stained by Oil Red O and Alizarin Red S, respectivelhBM-MSCs with FACS. Similar to wild-type hBM-MSCs,
minocycline-treated hBM-MSCs were strongly positive for
CD90, CD44, and CD73, and negative for CD34, CD45,
and HLA-DR (Figure 1B). The FACS analysis did not re-
veal a significant difference between wild-type hBM-MSCs
and minocycline-treated hBM-MSCs in the number of
surface markers (Figure 1B). The effect of minocycline on
hBM-MSCs differentiation potential was assessed by cul-
turing the cells in induction medium with or without
minocycline (10 μM) for 3 to 4 weeks. Minocycline did
not affect the differentiation ability to adipogenic or osteo-
genic lineages (Figure 1C). Furthermore, minocycline-
treated hBM-MSCs migrated and engrafted into the spinal
cords of EAE mice after intravenous administration (see
Additional file 1: Figure S1). Taken together, these results
suggest that the viability and characterization of hBM-
MSCs are not affected by minocycline.
Combined treatment improves the clinical score of EAE
mice
To evaluate the effect of combination treatment with
hBM-MSCs and minocycline on disease progression ind astrocyte viabilities were analyzed with the MTT assay 24 hours after
iability until 10 μM, whereas high concentrations (8 to 10 μM)
he effect of minocycline on hBM-MSC phenotype. Wild-type (black
ibodies for MSC phenotypic surface markers. Minocycline did not
D73 and lacked CD34, CD45, and HLA-DR. (C) The effect of
not affect the differentiation capability of hBM-MSCs to adipogenic or
y. The results are representative of three independent experiments.
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a combination of hBM-MSCs and minocycline into mice
7 days after immunization (n = 10/group). Neurologic
function was tested daily until 50 days after immuni-
zation. PBS-treated mice developed EAE with clinical
symptoms onset 10 days after immunization. Compared
with PBS treatment, treatment with hBM-MSCs or
minocycline postponed the onset of the clinical symp-
toms. hBM-MSCs-treated mice developed EAE with
clinical symptoms an average of 12.0 ± 1.80 days after
immunization (P = 0.0035, PBS versus hBM-MSCs treat-
ment). Minocycline-treated mice developed EAE with
clinical symptoms an average of 12.67 ± 1.0 days after
immunization (P < 0.001, PBS versus minocycline treat-
ment). The combination treatment significantly post-
poned clinical symptom onset compared with either
single treatment; the mice developed EAE an average of
14.5 ± 1.0 days after immunization (P < 0.001, hBM-
MSCs versus combination treatment; P = 0.007, minocy-
cline versus combination treatment) (Figure 2A). Com-
pared with PBS treatment, treatment with hBM-MSCs
or minocycline significantly decreased the average clinicalFigure 2 The combination of hBM-MSCs and minocycline attenuates
mice by immunization with the MOG 35- to 55-amino acid peptide. (A) Me
group) revealed that PBS-treated mice developed EAE with an average ma
minocycline alone decreased disease severity, with an average maximum s
disease severity, with an average maximum severity of grade 1. Points, mea
assessed from day 1 until day 50 after immunization. Compared with PBS t
decreased the average clinical scores (P < 0.05). Compared with hBM-MSCs
decreased the average clinical scores (P < 0.05). (C) The maximum clinical s
recorded, and the trend of the maximum clinical scores in the four groups
bars, SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with post hoc
independent experiments.scores (average clinical score in the PBS treatment,
3.166 ± 1.075; hBM-MSCs treatment, 1.433 ± 0.534; mino-
cycline treatment, 1.223 ± 0.4936; P < 0.001, PBS versus
hBM-MSCs treatment; P < 0.001, PBS versus minocycline
treatment) and the maximum clinical scores (PBS treat-
ment, 3.640 ± 1.284; hBM-MSCs treatment, 2.333 ±
0.6831; minocycline treatment, 2.033 ± 0.2582; P = 0.028;
PBS versus hBM-MSCs treatment; P = 0.014, PBS versus
minocycline treatment). The decreases in the combin-
ation-treatment group were much more significant com-
pared with either single treatment throughout the whole
disease course (average clinical scores of the combination-
treatment group, 0.7375 ± 0.3235, P = 0.005; hBM-MSCs
versus combination treatment, P = 0.031; minocycline ver-
sus combination treatment; maximal clinical score of the
combination-treatment group: 1.1625 ± 0.3292, P = 0.009
hBM-MSCs versus combination treatment; P = 0.024, mi-
nocycline versus combination treatment) (Figure 2B, C).
These results suggest that combination treatment with
hBM-MSCs and minocycline ameliorates clinical se-
verity and improves neurologic functional recovery of
EAE mice.clinical EAE severity in mice. EAE was induced in female C57 BL/6
an daily clinical scores for the different EAE treatments (n = 10 per
ximum severity over grade 4. Treatment with hBM-MSCs or
everity of grades 1 to 2. Combination treatment markedly attenuated
n; bars, SEM. (B) The average clinical score of the four groups was
reatment, hBM-MSCs or minocycline treatment alone significantly
or minocycline treatment alone, combination treatment significantly
core for each mouse over the course of the entire experiment was
was the same as the average clinical score (P < 0.05). Columns, mean;
Bonferroni corrections. The results are representative of three
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inflammatory cells in EAE mouse spinal cord
The improvement in clinical scores after combined
treatment may reflect decreased inflammatory cell infil-
tration into the CNS. To identify the effect of combin-
ation treatment on inflammatory-cell influx, sections of
lumbar spinal cords from EAE mice were labeled with
H&E and anti-CD4 to detect mononuclear cell and
T-cell infiltration, respectively. Infiltrated cells were
increased in spinal cord white matter in the PBS-
treatment group. However, these cells were reduced in
number after combined treatment compared with both
single treatments (Figure 3A). Stereologic analysis dem-
onstrated that hBM-MSCs or minocycline treatment
alone decreased the numbers of infiltrating cells com-
pared with the PBS treatment (P < 0.001, PBS versus
hBM-MSCs treatment; P < 0.001, PBS versus minocy-
cline treatment), and a further significant decrease oc-
curred in combination treatment mice compared with the
hBM-MSCs or minocycline treatment alone (P = 0.002,
hBM-MSCs versus combination treatment; P = 0.020,
minocycline versus combination treatment) (Figure 3B).
Furthermore, a significant decrease in CD4+ T-cell infiltra-
tion in the spinal cord of combination-treatment miceFigure 3 The combination of hBM-MSCs and minocycline decreases in
CD4 staining (bottom panel) were performed to detect mononuclear and T
indicate areas with infiltrated cells. Scale bar, 200 μm. (B) Statistical analysis
minocycline treatment alone significantly decreased the average clinical sc
alone, combination treatment significantly decreased the numbers of infiltr
minocycline treatment alone, combination treatment significantly decrease
bars, SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with post hoc
independent experiments.was evident compared with single treatment with hBM-
MSCs or minocycline (P < 0.001, hBM-MSCs versus
combination treatment: P = 0.003, minocycline versus
combination treatment) (Figure 3C).
Combined treatment reduces demyelination in the EAE
mouse spinal cord
To determine whether combination treatment reduced
tissue damage in EAE mice, sections of lumbar spinal
cords were labeled with LFB and anti-MBP. Demyelin-
ation was observed in lumbar spinal cord white matter
and was reduced to a greater extent by combined treat-
ment compared with either single treatment (Figure 4A).
Stereologic analysis of the extent of demyelination re-
vealed a significant reduction in mice treated solely with
hBM-MSCs or minocycline compared with the PBS-
treatment group (P < 0.001, PBS versus hBM-MSCs
treatment; P < 0.001, PBS versus minocycline treatment).
Moreover, a significant decrease was found in the com-
bination-treatment group compared with both single
treatments (P < 0.001, PBS versus combination treatment;
P = 0.017, hBM-MSCs versus combination treatment;
P = 0.038, minocycline versus combination treatment)
(Figure 4B). Furthermore, immunofluorescence stainingflammation in EAE mouse spinal cord. (A) H&E (upper panel) and
-cell infiltration in the lumbar spinal cords of EAE mice. The arrows
showing that compared with PBS treatment, hBM-MSCs or
ores (P < 0.05); compared with hBM-MSCs or minocycline treatment
ating cells by 20% to 30% (P < 0.05). (C) Compared with hBM-MSCs or
d the numbers of CD4+ cells by 30% to 40% (P < 0.05). Columns, mean;
Bonferroni corrections. The results are representative of three
Figure 4 The combination of hBM-MSCs and minocycline decreases demyelination in the EAE mouse spinal cord. (A) LFB- (upper panel)
and MBP-stained (bottom panel) spinal cord sections were assessed to detect the extent of demyelination in EAE mice. The arrows indicate
demyelinated areas. Scale bar, 200 μm. (B) Statistical analysis demonstrated that combination treatment significantly reduced demyelination
compared with hBM-MSCs or minocycline treatment alone (P < 0.05). (C) Combination treatment also significantly preserved the number of
MBP-positive cells compared with hBM-MSCs or minocycline treatment alone (P < 0.001). Columns, mean; bars, SEM. *P < 0.05, **P < 0.01,
***P < 0.001, one-way ANOVA with post hoc Bonferroni corrections. The results are representative of three independent experiments.
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spinal cords of the hBM-MSCs or minocycline treatment
groups compared with mice that received PBS (P = 0.048,
PBS versus hBM-MSCs treatment; P = 0.007, PBS versus
minocycline treatment. The intensity of labeling for MBP-
positive cells significantly increased in the combination-
treatment group compared with hBM-MSCs or mino-
cycline treatment alone (P = 0.005, hBM-MSCs versus
combination treatment; P = 0.003, minocycline versus
combination treatment) (Figure 4C). Thus, these results
suggest that combination treatment with hBM-MSCs and
minocycline reduced tissue damage and alleviated the
clinical symptoms of EAE.
Combined treatment reduces neuroinflammation and
neurodegeneration in EAE mouse spinal cord
Neuroinflammation and neurodegeneration were eval-
uated by analyzing GFAP-, Iba-1-, and NeuN-positive
cells. In PBS-treated EAE mice, intense glial activation
with increases in the number of cells intensely stained
for GFAP and Iba-1 in the lesion area was evident.
In EAE mice treated with hBM-MSCs or minocycline
alone, we observed a decreased number of astrocytes
and microglia cells compared with PBS-treated EAE
mice. Only a small number of GFAP- and Iba-1-positive
astrocytes and microglia cells, respectively, were observedin the combination-treatment mice (Figure 5A). Stereolo-
gic analyses of GFAP- and Iba-1-positive cells demon-
strated significant reductions in the fluorescence intensity
of labeling for activated astrocytes and the number of acti-
vated microglia cells after treatment with hBM-MSCs or
minocycline alone, compared with the PBS treatment
(GFAP: P < 0.001, PBS versus hBM-MSCs treatment;
P < 0.001, PBS versus minocycline treatment; Iba-1:
P = 0.002, PBS versus hBM-MSCs treatment; P = 0.001,
PBS versus minocycline treatment). A significant re-
duction was noted in the combination-treatment group
compared with either single treatment (GFAP: P < 0.001,
hBM-MSCs versus combination treatment; P < 0.001,
minocycline versus combination treatment; Iba-1:
P = 0.009, hBM-MSCs versus combination treatment;
P = 0.024, minocycline versus combination treatment)
(Figure 5B, C).
Next, we evaluated the neuroprotection conferred by
each treatment by counting the number of neurons in
the gray matter of lumbar spinal cord sections. The
number of NeuN-positive neurons increased in the gray
matter of EAE mice treated with hBM-MSCs or mino-
cycline alone compared with the PBS treatment, whereas
the combination treatment induced a marked increase in
NeuN immunoreactivity. Stereologic analysis verified a
significant increase in the number of NeuN-positive cells
Figure 5 Combined treatment reduces glial reactivity and protects neurons in the EAE mouse spinal cord. (A) Sections are labeled for
GFAP (upper panel), Iba-1 (middle panel), and NeuN (bottom panel) immunoreactivity to detect astrocytes, microglia, and neurons, respectively.
Intense GFAP immunoreactivity was present in PBS-treated EAE mice and was reduced in EAE mice treated with hBM-MSCs or minocycline alone,
but fewer astroglial cells were activated in the combination-treatment group. Iba-1, which identifies activated microglia, displayed the same
immunoreactivity patterns as GFAP in the four EAE groups. The opposite pattern was observed for the neuronal marker, NeuN, in all groups. Scale
bar, 200 μm. (B) Stereologic analyses of GFAP fluorescence intensity and (C) the number of Iba-1-positive cells revealed significant reductions in
astrocytes and microglial activation in combination-treatment mice compared with those treated with hBM-MSCs or minocycline alone (P < 0.05).
(D) Stereologic analysis also revealed a significant increase in the number of NeuN-positive cells in spinal cord sections of EAE mice treated with
both hBM-MSCs and minocycline compared with hBM-MSCs or minocycline treatment alone (P < 0.01). Columns, mean; bars, SEM. *P < 0.05,
**P < 0.01, ***P < 0.001, one-way ANOVA with post hoc Bonferroni corrections. The results are representative of three independent experiments.
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MSCs or minocycline alone compared with the PBS
treatment (P = 0.016, PBS versus hBM-MSCs treatment;
P = 0.004, PBS versus minocycline treatment). However,
compared with the treatment with hBM-MSCs or
minocycline alone, a significant increase was noted in
the combination-treatment group (P < 0.001, hBM-MSCs
versus combination treatment; P < 0.001, minocycline ver-
sus combination treatment) (Figure 5D). Taken together,
these results suggest that combination treatment with
hBM-MSCs and minocycline alleviates neurodegeneration
and reduces neuroinflammation in the CNS, mitigates the
clinical symptoms of EAE.
Combined treatment promotes a shift from Th1 to Th2
cytokine balance in EAE mice
To determine whether the combination treatment would
modulate inflammatory cytokine expression, we evalu-
ated the systemic expression of IFN-γ/TNF-α and IL-4/
IL-10 cytokines in EAE mice sera with ELISA. We ob-
served a significant decrease of IFN-γ/TNF-α Th1 cyto-
kines and an increase of IL-4/IL-10 Th2 cytokines
expression in the hBM-MSCs or minocycline treatment
groups compared with the PBS-treatment group (IFN-γ:
P = 0.010, PBS versus hBM-MSCs treatment; P = 0.005,
PBS versus minocycline treatment; TNF-α: P = 0.042,
PBS versus hBM-MSCs treatment; P = 0.009, PBS versus
minocycline treatment; IL-4: P = 0.004, PBS versus hBM-MSCs treatment; P = 0.001, PBS versus minocycline
treatment; IL-10: P = 0.022, PBS versus hBM-MSCs
treatment; P = 0.008, PBS versus minocycline treatment)
(Figure 6). In addition, we detected a significant decrease
of IFN-γ/TNF-α Th1 cytokines and an increase of IL-4/
IL-10 Th2 cytokines in the combination treatment group
compared with both single-treatment groups (IFN-γ:
P = 0.006, hBM-MSCs versus combination treatment;
P = 0.048, minocycline versus combination treatment;
TNF-α: P = 0.006, hBM-MSCs versus combination treat-
ment; P = 0.009, minocycline versus combination treat-
ment; IL-4: P < 0.001, hBM-MSCs versus combination
treatment; P < 0.001, minocycline versus combination
treatment; IL-10: P = 0.028, hBM-MSCs versus combi-
nation treatment; P = 0.043, minocycline versus combi-
nation treatment) (Figure 6).
Furthermore, because the initial immune reactions
take place in the periphery before immune cell migration
into the CNS, we examined the effect of all treatments
on the systemic immune microenvironment in an
in vitro system. IFN-γ and IL-4 production were asses-
sed in anti-MOG35-55-stimulated splenocytes isolated
from all EAE groups. The analysis revealed a significant
decrease of IFN-γ and a significant increase of IL-4 pro-
duction in the hBM-MSCs or minocycline treatment
groups compared with the PBS-treatment group (IFN-γ:
P = 0.006, PBS versus hBM-MSCs treatment; P < 0.001,
PBS versus minocycline treatment; IL-4: P = 0.042, PBS
Figure 6 Combination treatment promotes a shift from the Th1 to Th2 cytokine balance in EAE mice. Sera were isolated from the five
groups of EAE mice 40 days after immunization. Cytokine protein-expression levels in the serum were quantified with ELISA. (A) Stereologic
analysis demonstrated a significant decrease of IFN-γ/TNF-α Th1 cytokines in the hBM-MSCs or minocycline-treatment groups compared with
PBS treatment, and a similar expression pattern was evident in the combination-treatment group compared with hBM-MSCs or minocycline
treatment-alone groups. (B) Significant increases were present in IL-4 and IL-10 protein-expression levels in the hBM-MSCs or minocycline-treatment
groups compared with PBS treatment, and the same pattern was evident in the combination-treatment mice compared with hBM-MSCs or
minocycline treatment alone. Columns, mean; bars, SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with post hoc Bonferroni corrections.
The results are representative of three independent experiments.
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minocycline treatment). The same pattern was also detec-
ted in the combination treatment, but the effect was sig-
nificantly greater than observed in the single treatment
groups (IFN-γ: P = 0.025, hBM-MSCs versus combination
treatment; P = 0.037, minocycline versus combination
treatment; IL-4: P = 0.039, hBM-MSCs versus combin-
ation treatment; P = 0.046, minocycline versus combin-
ation treatment) (see Additional file 2: Figure S2). These
results suggest that the combination treatment of hBM-
MSCs and minocycline systemically affect the effector
phase of EAE. Collectively, it appears that a significant
shift occurs from the Th1 to Th2 cytokine balance in the
combination-treatment EAE mice.
Combined treatment reduces apoptotic cell death in EAE
mouse spinal cord
To investigate whether the combination treatment could
protect injured spinal cord cells from apoptosis, apop-
totic cell death was examined with TUNEL staining. The
number of apoptotic cells was reduced in the single-
treatment groups compared with the PBS-treated group
(P < 0.001, PBS versus hBM-MSCs treatment; P < 0.001,
PBS versus minocycline treatment), but the combination
treatment group exhibited a more significant decrease
in the number of apoptotic cells compared with the
groups treated with hBM-MSCs or minocycline alone
(P < 0.001, hBM-MSCs versus combination treatment;
P = 0.002, minocycline versus combination treatment)(Figure 7). Thus, during EAE, apoptotic cell death in
the lesion sites was reduced by combination treatment. In
addition, we confirmed that most apoptotic cells were
double labeled with NeuN, the neuronal marker, whereas
only a few were positive for GFAP, Iba-1, or CD4 (see
Additional file 3: Figure S3). These results suggest that
combination treatment could decrease neuronal death in
EAE mouse spinal cord.
Discussion
A therapeutic approach to improve MS treatment is to
identify an effective combination of new medications or
existing therapies that affect different aspects of the dis-
ease process and mitigate the adverse events by using
lower doses of individual drugs as a combination therapy
[22]. One issue to consider is that such a combination
could synergistically produce adverse effects or events.
Minocycline has multiple immunomodulatory and neuro-
protective activities [23], but it can also cause side effects,
such as systemic lupus erythematosus and serum sickness
[9,10] and is toxic to the nervous system [11,12]. We
found that high doses of minocycline decreased astrocyte
viability. We also tested the effects of minocycline on
hBM-MSCs and found that it did not affect their viability
or characteristics, even at a high dose. As hBM-MSCs and
minocycline meet the combined-therapy criteria, it is rea-
sonable to test their combination-therapy efficacy in MS.
Presently, although hBM-MSCs or a low-dose mino-
cycline treatment alone had significant effects on EAE
Figure 7 hBM-MSCs and minocycline in combination reduce apoptosis in EAE mouse spinal cord. (A) Apoptotic cell death was examined
with TUNEL staining. TUNEL-positive cells are red, and counterstaining for DAPI is blue. Scale bar, 200 μm. (B) TUNEL-positive cells were also
quantified with MetaMorph image analysis. A statistically significant reduction in the number of apoptotic cells in the hBM-MSCs or minocycline
treatment-alone group compared with the PBS-treated group (P < 0.001), and the combination treatment showed a more significant decrease in
apoptosis compared to hBM-MSCs or minocycline treatment alone (P < 0.001). Columns, mean; bars, SEM. **P < 0.01, ***P < 0.001, one-way ANOVA
with post hoc Bonferroni corrections. The results are representative of three independent experiments.
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treatment further protected EAE mice from disease pro-
gression along with significant attenuation of disease
severity, reductions in inflammatory infiltration, demye-
lination, neurodegeneration, and enhancement of the im-
munomodulatory function. Many possible mechanisms
exist for the effects of combination treatment: the first
beneficial effect of the combination treatment might in-
volve modulation of the expression/production of IFN-γ/
TNF-α and IL-4/IL-10 in the serum and splenocyte cul-
tures of EAE mice in this study.
Cytokines play an important role in MS pathogenesis,
as well as in EAE [24]. The balance between Th1 and
Th2 in the CNS may be the key determinant in the de-
velopment of EAE, which is a Th1-mediated disease
[25,26]. In contrast, Th2 cytokines have been associated
with remission and recovery [27]. In organ-specific auto-
immunity, the cytokine balance is pivotal in the deter-
mination of resistance or susceptibility [28,29]. EAE
susceptibility is thought to correlate with the expression
of IFN-γ and TNF-α, which are the primary proinflam-
matory Th1 cytokines, whereas Th2 cytokines, such as
IL-4 and IL-10, are antiinflammatory cytokines impor-
tant for preventing or ameliorating disease [30]. TNF-α
/IFN-γ and IL-4/IL-10 are considered the hallmark cyto-
kines that direct Th1 and Th2 development and play an
important role in both MS and EAE pathogenesis. Our
finding that the combination treatment promoted a shift
from the Th1 to Th2 cytokine balance in EAE mice is in
accordance with previous observations that minocycline
modulates immune differentiation from a Th1 toward aTh2 phenotype; therefore reducing T-cell infiltration into
the spinal cord in MS and EAE [2,5,31]. Furthermore,
hBM-MSCs are able to suppress T-lymphocyte activation
and proliferation, induce Th2-polarized immune response,
and promote endogenous repair, thus exerting immuno-
modulatory effects both in vitro and in vivo [14-17]. Our
observations that the combination treatment of hBM-
MSCs and minocycline exceeded the effects of either
treatment alone indicate effective synergistic function.
The second possible mechanism is inhibition of in-
flammation and glial activation. Inflammation is consid-
ered a cause of tissue damage during relapsing-remitting
MS and EAE. Therefore, antiinflammation continues to
be the primary therapeutic objective during early MS
[32]. Glial activation is thought to play a crucial role in
tissue destruction through the production of proinflam-
matory cytokines and massive proliferation that may
overwhelm the surrounding cells. In our study, hBM-
MSCs or minocycline alone, as well as combination
treatment, significantly decreased mononuclear and T-
cells infiltration, and microglial and astrocyte activation.
The data presented here agree with the previous obser-
vation that inhibition of glial cell activation ameliorates
EAE severity [33] and that minocycline is neuroprotec-
tive by inhibiting microglial activation [8,34,35]. Trans-
planted hBM-MSCs provide a feasible and practical
means of neuroprotection by decreasing microglial and
astrocyte activation; they also reduce apoptosis by se-
creting neurotrophic factors, remyelinating focal de-
myelination lesions in the spinal cord, and improving
functional outcome after spinal cord injury [18,36-40].
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therapy effect of this combination treatment in EAE
mice.
In addition, a recent study reported that minocycline
induces neuroprotection not due to its antiinflammatory
action, but directly through the induction of antiapop-
totic intracellular signaling pathways [4]. These observa-
tions are consistent with the present observation that
combined treatment with hBM-MSCs and minocycline
significantly decreased apoptosis in the lesion sites of
EAE mice.
Conclusions
The combination of hBM-MSCs and minocycline exerts
effective therapy effects by promoting a shift from Th1
to Th2 cytokine balance, decreasing inflammatory cell
influx, suppressing demyelination, reducing apoptosis,
enhancing neuroprotection, and preventing disease pro-
gression in EAE mice. Our results indicate that this
therapeutic strategy is a promising approach for the
treatment of MS.
Additional files
Additional file 1: Figure S1. Identification of minocycline-treated
hBM-MSCs in the spinal cord of EAE mice. hBM-MSCs infected with
Ad-GFP (50 MOI) were treated with minocycline (10 μM). Five days after
minocycline-treated hBM-MSCs (1.5 × 106) administration, hBM-MSCs
were visualized by using a Zeiss LSM 700 confocal microscope. (A) The
GFP-transduced hBM-MSCs (green) distributed in the lesion area; many
of them were closely associated with blood vessels. (a) The high
magnification of the boxed area in (A). Nuclei were counterstained with
DAPI (blue). The arrows indicate GFP-positive cells. Scale bar = 1 mm in
(A), Scale bar = 200 μm in (a).
Additional file 2: Figure S2. Combined treatment reduces frequency
of Th1 but increases frequency of Th2 in EAE mice. Splenocytes
(5 × 105/well) isolated from EAE mice at day 40 after immunization were
stimulated with MOG35-55. The number of MOG-specific IFN-γ (A)/IL-4 (B)
producing splenocytes was determined with enzyme-linked immunospot
(ELISPOT) assay. Combination treatment significantly decreased
frequencies of Th1, but increased frequencies of myelin peptide-specific
Th2 compared with hBM-MSCs or minocycline treatment alone (P < 0.05).
The wells shown are representatives of triplicates. Columns, mean; bars,
SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with post hoc
Bonferroni corrections. The results are representative of three
independent experiments.
Additional file 3: Figure S3. Characterization of the apoptotic cells in
the lumbar spinal cords of the EAE mice. (A) Sections were double
labeling of TUNEL (red) with NeuN (green) in the white matter of the
lumbar spinal cords. (a) High magnification of the boxed area in (A);
most apoptotic cells were positive for NeuN (arrows in a). (B) Double
labeling of TUNEL (red) with GFAP (green) in the white matter of the
lumbar spinal cords. (b) High magnification of the boxed area in (B); a
few apoptotic cells were positive for GFAP (arrows in b). (C) Double
labeling of TUNEL (red) with Iba-1 (green) in the white matter of the
lumbar spinal cords. (c) High magnification of the boxed area in (C); a
few apoptotic cells were positive for Iba-1 (arrows in c). (D) Double
labeling of TUNEL (red) with CD4 (green) in the white matter of the
lumbar spinal cords. (d) High magnification of the boxed area in (D); a
few apoptotic cells were positive for CD4 (arrows in d). Nuclei were
counterstained with DAPI (blue). The arrows indicate positive cells. Scale
bars = 200 μm in (A through D), Scale bars = 100 μm in (a through d).Abbreviations
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